All In Biotech

Drug Trial Radar · NCT07216079

Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan

An Open-label Extension Study for Oral Rilzabrutinib in Adults With Chronic Immune Thrombocytopenia (ITP) Who Have Completed the Long-term Extension (LTE) of the LUNA 3 Study (PRN1008 018/EFC17093) in Japan

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

3

Actual

Start

Oct 15, 2025

Primary completion

Nov 25, 2026

Study completion Nov 25, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, single group, Phase 3 study for treatment with rilzabrutinib. The purpose of this study is to provide continuation of rilzabrutinib treatment to adult participants with ITP who have completed the LTE of the LUNA 3 study in Japan, demonstrating clinically meaningful benefit as judged by the Investigator.

Conditions

  • Immune Thrombocytopenia

Interventions

  • rilzabrutinibDrug

    Pharmaceutical form:Tablet-Route of administration:Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AEs including SAEs and AESIsTime frame: Until study completion, approximately 60 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number: 1001

    Tsuchiura, Ibaraki, Japan

  • Investigational Site Number: 1002

    Kanazawa, Ishikawa-ken, Japan

  • Investigational Site Number: 1003

    Iruma-gun, Saitama, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.